Cargando…
Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
OBJECTIVE: To assess the reversibility of the elevation of serum creatinine levels in patients with diabetes after 5 years of continuous on-trial fenofibrate therapy. RESEARCH DESIGN AND METHODS: An on-drug/off-drug ancillary study to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Li...
Autores principales: | Mychaleckyj, Josyf C., Craven, Timothy, Nayak, Uma, Buse, John, Crouse, John R., Elam, Marshall, Kirchner, Kent, Lorber, Daniel, Marcovina, Santica, Sivitz, William, Sperl-Hillen, JoAnn, Bonds, Denise E., Ginsberg, Henry N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329840/ https://www.ncbi.nlm.nih.gov/pubmed/22432114 http://dx.doi.org/10.2337/dc11-1811 |
Ejemplares similares
-
PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid
por: Morieri, Mario Luca, et al.
Publicado: (2020) -
Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD
por: Shah, Hetal S., et al.
Publicado: (2018) -
Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial
por: Linz, Peter E., et al.
Publicado: (2014) -
Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage
por: Mychaleckyj, Josyf C, et al.
Publicado: (2011) -
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial
por: Morieri, Mario Luca, et al.
Publicado: (2018)